The Heated Tobacco Gamble: Philip Morris's $10 Billion Bet on a Product Nobody Asked For

When Philip Morris International launched IQOS in Nagoya, Japan, in 2014, the ambition was audacious: replace the combustible cigarette—the product that had defined the company for over a century—with a device that heats tobacco without burning it. The technology is simple in concept: a blade (or induction coil, in later models) heats a specially-designed tobacco stick to approximately 350°C, producing a nicotine-containing aerosol without the combustion that generates the vast majority of cigarette smoke's toxicants. PMI invested over $10 billion in IQOS development, manufacturing, and marketing—the largest product pivot in the history of the tobacco industry. The company's stated goal: over 50% of revenue from smoke-free products by 2025. IQOS was supposed to be the product that got them there.

The Japanese experiment was extraordinary—and extraordinarily successful. Within five years of launch, cigarette sales in Japan declined by over 40%, a rate of decline unprecedented in any major market in peacetime history. IQOS captured over 25% of the Japanese nicotine market, and the rate of smoking decline accelerated with every quarter of IQOS availability. The mechanism was not primarily switching from cigarettes to IQOS among existing smokers (though that happened). It was that new nicotine users—young adults entering the category—were choosing IQOS instead of cigarettes, and existing smokers were quitting cigarettes entirely more often. The Japanese data provided the strongest real-world evidence to date that a non-combustible nicotine product, made widely available, could displace cigarettes at a population level.

The global rollout has been more complicated. IQOS has been successful in several markets—Italy, South Korea, Eastern Europe—and has struggled in others, including the United States, where PMI's licensing agreement with Altria created a messy dual-distribution arrangement that limited market penetration. The regulatory pathway has been contentious: FDA authorized IQOS for sale in the US in 2019 and granted 'modified risk tobacco product' orders in 2020, allowing PMI to market IQOS as having reduced exposure to harmful chemicals compared to cigarettes. Anti-tobacco advocates challenged the decision, arguing that reduced exposure does not necessarily mean reduced harm, and that the long-term health effects of heated tobacco are unknown. The FDA's independent review acknowledged the remaining uncertainties but concluded that the available evidence—chemical analysis, toxicological studies, and short-term clinical data—supported the reduced-exposure claim.

The public health community's response to heated tobacco has been even more polarized than its response to vaping—if that's possible. The anti-harm-reduction camp views IQOS as a Trojan horse: a product designed to perpetuate nicotine addiction while providing an illusion of reduced risk. They point to PMI's continued sale of combustible cigarettes, the company's marketing practices in low-income countries, and the absence of long-term epidemiological data. The pro-harm-reduction camp views IQOS as a public health opportunity: a product that delivers nicotine with substantially fewer toxicants than cigarettes, produced by a company with the resources and regulatory expertise to navigate the PMTA process, and with real-world evidence from Japan suggesting it can displace cigarettes at a population level. Both positions have evidence to support them. Neither is complete.

The strategic calculus for PMI is that IQOS is a bridge: a product that can transition the company's existing cigarette consumers to a lower-risk platform while the regulatory and competitive landscape for vaping and pouches evolves. The long-term economics depend on whether IQOS can capture enough of the cigarette market to offset the declining cigarette revenue, and whether the regulatory environment allows IQOS to compete on price and consumer experience with both cigarettes and vaping products. The Japanese data suggests it can work. The global data is less clear. The outcome will depend on decisions that PMI does not fully control: regulatory frameworks in key markets, the pace of scientific evidence accumulation, the competitive response from other nicotine categories, and the political dynamics of tobacco control in an era of polarized harm reduction debates.

For the broader nicotine industry, IQOS represents a strategic experiment with implications that extend far beyond PMI. If heated tobacco succeeds as a category—if it demonstrably reduces population-level harm by displacing cigarettes—it validates the industry's 'smoke-free future' narrative and strengthens the case for regulatory frameworks that encourage switching. If it fails—if it remains a niche product, or if long-term data reveals health risks that are closer to smoking than to vaping—it undermines the industry's transformation narrative and strengthens the case for the abstinence-only approach. The stakes are high: not just for PMI's shareholders, but for the billion-plus smokers whose health outcomes depend on whether safer products are available and appealing. The IQOS experiment is not just a business bet. It's a public health bet—one whose outcome we won't fully understand for another decade.

Shareable insight: PMI spent $10 billion developing a product that doesn't burn tobacco—because burning tobacco is what kills people. Whether this represents genuine transformation or the most expensive marketing campaign in history depends on outcomes that are still unfolding.